Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luisetti, M.
Right arrow Articles by Travis, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luisetti, M.
Right arrow Articles by Travis, J.
(Chest. 1996;110:278S-283S.)
© 1996 American College of Chest Physicians

Bioengineering: agr1-Proteinase Inhibitor Site-Specific Mutagenesis

The Prospect for Improving the Inhibitor

Maurizio Luisetti MD, FCCP1 and James Travis PhD2

1 From the Istituto di Tisiologia e Malattie Apparato Respiratorio, Università di Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
2 From the Department of Biochemistry, University of Georgia, Athens

agr1-Proteinase inhibitor (agr1-PI) augmentation therapy has been licensed for treatment of agr1-PI-deficient individuals with pulmonary emphysema. The currently available product is purified from pooled human plasma. To obtain larger amounts of protein free from possible unknown plasma contaminants, human agr1-PI has been produced by recombinant DNA. Since wild-type agr1-PI is susceptible to oxidative impairment, several agr1-PI variants in which the active site oxidation-sensitive residue is replaced by inert residues have been constructed. This article is aimed at reviewing the history, biological efficacy, advantages, disadvantages, and concerns linked to agr1-PI recombinant DNA and site-specific mutagenesis technology.

Key Words: agr1-PI deficiency • neutrophil elastase • oxidants • pulmonary emphysema • recombinant DNA






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Chest Physicians.